Quick title

FUSE Code1

For your C3G and IgA Nephropathy patients life outside your office can be more challenging than imagined.

red-flower

Glomerular Disease & Your Patients

Glomerulonephritides are a set of rare kidney diseases that are characterized by inflammation of the glomeruli¹

Glomerular diseases have an incidence of 0.5-2.5 per 100,000 people.

Complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN) are 2 complement-mediated diseases that can cause permanent kidney damage and have limited targeted treatment options. Patients face continued disease progression and significant burdens that may impact their day-to-day lives.^2,3

Beyond the statistics, patients with C3G and IgAN can struggle with:

Beyond the statistics, patients with C3G and IgAN struggle

Get updates and resources from Novartis

Sign up for more information on complement-mediated glomerular disease

Understand C3G, a progressive kidney disease

Learn more about IgAN, a chronic kidney disease

Swipe left, or click and drag

Novartis is committed to addressing unmet needs of people living with complement-mediated diseases

References: 1. Nanchen G, Schutzbach K, Rotman S, et al. Incidence of glomerulonephritis in the western part of Switzerland over the last decade. Swiss Med Wkly. 2020;150:w2035. doi:10.4414/smw.2020.20353 2. Lafayette RA, Kelepouris E. Immunoglobulin A nephropathy: advances in understanding of pathogenesis and treatment. Am J Nephrol. 2018;47(suppl 1):43-52. doi:10.1159/000481636 3. Smith RJH, Appel GB, Blom AM, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129-143. 4. Feldman DL, White EM, Julian B, et al. The Voice of the Patient: Externally Led Patient-Focused Drug Development Meeting on IgA Nephropathy. National Kidney Foundation; 2020. 5. Feldman DL, Bomback A, Nester CN. Voice of the Patient: Report of Externally Led Patient-Focused Drug Development Meeting on Complement 3 Glomerulopathy (C3G). National Kidney Foundation; 2018.